Nambrol Adulti (Flunisolide)

Flunisolide, the active ingredient in Nambrol Adulti, is a corticosteroid presented as an inhalation formulation for respiratory use. It is prescribed to reduce airway inflammation in patients with asthma and related respiratory conditions.

GNH USA supplies Nambrol Adulti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Flunisolide is a corticosteroid that reduces airway inflammation in respiratory disorders.

- Asthma: provides maintenance therapy to control persistent symptoms and prevent exacerbations. - Chronic bronchial hyperresponsiveness: diminishes airway reactivity to triggers. - Allergic airway disease: alleviates inflammation associated with allergic triggers.

Inhaled flunisolide may cause a range of adverse reactions, most of which are related to local airway exposure.

Common Side Effects: - Oral thrush: fungal infection of the mouth and throat. - Hoarseness or dysphonia: voice changes due to laryngeal irritation. - Cough or throat irritation: transient discomfort after inhalation. - Headache: mild to moderate intensity. - Sore throat: irritation of the oropharynx.

Serious or Rare Side Effects: - Adrenal suppression: reduced endogenous cortisol production. - Pneumonia: increased susceptibility to lower respiratory infections. - Cataracts or glaucoma: ocular pressure changes with long‑term use. - Severe allergic reaction: anaphylaxis or angioedema. - Immunosuppression: heightened risk of systemic infections.

When prescribing inhaled flunisolide, clinicians should consider several safety measures.

- Monitor growth in children: assess height regularly during long‑term therapy. - Assess for oral candidiasis: advise rinsing mouth after each use. - Avoid abrupt discontinuation: taper dose to prevent adrenal insufficiency. - Use a spacer device: reduces oropharyngeal deposition and side effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Flunisolide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Ketoconazole: may increase systemic corticosteroid exposure. - Ritonavir: can raise flunisolide plasma levels. - Systemic corticosteroids: additive immunosuppressive effects.

Moderate Interactions (Monitor Closely): - Beta‑agonists: may mask worsening asthma symptoms. - Diuretics: potential for hypokalemia when combined with systemic steroids. - Anticholinergics: may affect inhalation technique and drug deposition.